[Effects of herpes simplex virus thymidine kinase gene transduction and prodrug on ovarian cancer cell].
To evaluate the efficacy of gene therapy with the herpes simplex virus thymidine kinase (HSV-TK) gene transference followed by ganciclovir (GCV) therapy in ovarian cancer. HSV-TK gene was inserted into the hind III site of pLNSX vector and recombinant plasmid (pLNS/HSV-TK) was constracted. Then, the recombinant plasmid was transfered into PA317 packaged cell and the producer cell line of recombinant retrovirus vector pLNS/HSV-TK was established. The cytotoxicity efficacy of HSV-TK/GCV system to AO cell line was evaluated by microcucture tetrajolium test (MTT) method. The recombinant retroviral vector pLNS/HSK-TK can transfer HSV-SK gene into the genome of AO cell line and make it sensitive to GCV. The growth inhibitory rate of AO cell line transfered by pLNS/HSV-TK was 98.0% in the medium containing 400 mumol GVC. The ovarian cancer cell line transfered by HSV-TK gene regressed rapidly in response to the GCV therapy.